BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings

BIOXYTRAN, INC

Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.
Restatement driven by misvaluation of shares under Rule 3(a)(9) and Rule 701, and timing errors in accruals.
Company engaged Fruci & Associates as successor auditor after SEC denied BF Borgers privilege.
Common stock adjusted (1M shares returned to treasury in 2023; 93,750 shares added in 2022).
No net impact on cash flows from operations, investing, or financing.

item 4.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.

Action: engagement
Auditor: Fruci & Associates II, PLLC

Exact text from the filing

the Company engaged Fruci & Associates II, PLLC ("Fruci"), PCAOB ID # 05525, as their successor auditor in order to re-audit the Financial Statements for the years ended December 31, 2023 and 2022.

View on SEC.gov

47 auditor changes filed in the last 30 days. Browse all auditor changes →

BIOXYTRAN, INC filing history →

Source: SEC EDGAR

accession 0001493152-25-001891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.